SPARC reported a massive FY26 standalone net profit of ₹15,521 crore, a dramatic turnaround from a ₹3,452 crore loss in FY25, driven by a ₹18,400 crore Priority Review Voucher sale.
The company received and sold a USFDA Priority Review Voucher for Sezaby® for USD 195 million, recognized as other operating revenue in Q4 FY26.
The Board approved audited standalone and consolidated financial results for Q4 and FY26, with auditors issuing an unmodified opinion on both sets of results.